Eyenovia, Inc.

Equities

EYEN

US30234E1047

Pharmaceuticals

Real-time Estimate Cboe BZX 12:29:22 2024-03-28 pm EDT 5-day change 1st Jan Change
0.966 USD -2.07% Intraday chart for Eyenovia, Inc. -18.47% -53.75%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Eyenovia, Inc., Q4 2023 Earnings Call, Mar 18, 2024
Eyenovia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Investors -2- DJ
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals CI
Eyenovia Reports FDA Approval for Formosa's Post-Op Eye Inflammation, Pain Treatment MT
US FDA approves Eyenovia's eye drug, Formosa Pharma says RE
Eyenovia, Inc Announces FDA Approval of Redwood City as Commercial Manufacturing Facility CI
Eyenovia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Eyenovia, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Eyenovia, Inc. Appoints Michael Geltzeiler to Serve on the Board and as the Chair of the Audit Committee of the Board CI
Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production CI
William Blair Initiates Eyenovia at Outperform Rating MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday MT
Eyenovia Prices $12 Million Registered Direct Offering MT
Insider Buy: Eyenovia MT
Eyenovia Acquires US Rights to Eye Surgery Drug From Formosa MT
Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of App13007 for the Treatment of Inflammation and Pain Following Ocular Surgery CI
Transcript : Eyenovia, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Eyenovia, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Eyenovia, Inc. Announces First Commercial Sale of Mydcombi CI
Eyenovia, Inc.(NasdaqCM:EYEN) added to Russell 3000 Index CI
Eyenovia, Inc.(NasdaqCM:EYEN) added to Russell 3000E Growth Index CI
Eyenovia, Inc.(NasdaqCM:EYEN) added to Russell 3000E Index CI
Eyenovia, Inc.(NasdaqCM:EYEN) added to Russell Small Cap Completeness Index CI
Eyenovia, Inc.(NasdaqCM:EYEN) added to Russell 2000 Growth Index CI
Chart Eyenovia, Inc.
More charts
Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9864 USD
Average target price
9.333 USD
Spread / Average Target
+846.20%
Consensus
  1. Stock
  2. Equities
  3. Stock Eyenovia, Inc. - Nasdaq
  4. News Eyenovia, Inc.
  5. Eyenovia : FDA Reclassifies Eyenovia's MydCombi as Drug-Device Combination Product